<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006420.pub2" GROUP_ID="RENAL" ID="641505112407522660" MERGED_FROM="" MODIFIED="2016-08-10 22:53:33 +0100" MODIFIED_BY="Narelle Willis" REVIEW_NO="045" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.2">
<COVER_SHEET MODIFIED="2016-08-11 07:50:20 +1000" MODIFIED_BY="Narelle Willis">
<TITLE MODIFIED="2012-08-03 22:25:38 +1000" MODIFIED_BY="Jesus Lopez-Alcalde">Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units</TITLE>
<CONTACT>
<PERSON ID="C106432182E26AA2007834EBF3D23A1A" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jessica</FIRST_NAME>
<MIDDLE_INITIALS>I</MIDDLE_INITIALS>
<LAST_NAME>Bravo Zuñiga</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Investigator</POSITION>
<EMAIL_1>ivobz@yahoo.es</EMAIL_1>
<EMAIL_2>cmnefro@upch.edu.pe</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Universidad Peruana Cayetano Heredia</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Lima</CITY>
<ZIP>031</ZIP>
<REGION/>
<COUNTRY CODE="PE">Peru</COUNTRY>
<PHONE_1>+51 14819878</PHONE_1>
<PHONE_2>+51995020905</PHONE_2>
<FAX_1>+51 14820828</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-08-11 07:50:20 +1000" MODIFIED_BY="Narelle Willis">
<PERSON ID="C106432182E26AA2007834EBF3D23A1A" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jessica</FIRST_NAME>
<MIDDLE_INITIALS>I</MIDDLE_INITIALS>
<LAST_NAME>Bravo Zuñiga</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Investigator</POSITION>
<EMAIL_1>ivobz@yahoo.es</EMAIL_1>
<EMAIL_2>cmnefro@upch.edu.pe</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Universidad Peruana Cayetano Heredia</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Lima</CITY>
<ZIP>031</ZIP>
<REGION/>
<COUNTRY CODE="PE">Peru</COUNTRY>
<PHONE_1>+51 14819878</PHONE_1>
<PHONE_2>+51995020905</PHONE_2>
<FAX_1>+51 14820828</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="3B1D082B82E26AA2010EE5B88DFEAF08" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>César</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Loza Munárriz</LAST_NAME>
<SUFFIX/>
<POSITION>Head</POSITION>
<EMAIL_1>cesar.loza@upch.pe</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>51-1999973542</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Universidad Peruana Cayetano Heredia</ORGANISATION>
<ADDRESS_1>Hospital Cayetano Heredia</ADDRESS_1>
<ADDRESS_2>Honorio Delgado 420</ADDRESS_2>
<CITY>Lima</CITY>
<ZIP>31</ZIP>
<REGION/>
<COUNTRY CODE="PE">Peru</COUNTRY>
<PHONE_1>+51 14622024</PHONE_1>
<PHONE_2>+51 13818215</PHONE_2>
<FAX_1>+51 13818215</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="EF8630AA82E26AA201B664BB681855E6" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Jesús</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>López-Alcalde</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher</POSITION>
<EMAIL_1>cochrane.madrid@ufv.es</EMAIL_1>
<EMAIL_2>suso77@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Unidad de bioestadística clínica</DEPARTMENT>
<ORGANISATION>Hospital Universitario Ramón y Cajal (IRYCIS). CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION>
<ADDRESS_1>Ctra. Colmenar, km. 9.100</ADDRESS_1>
<ADDRESS_2/>
<CITY>Madrid</CITY>
<ZIP>28034</ZIP>
<REGION>Madrid</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 913368103</PHONE_1>
<PHONE_2/>
<FAX_1>+34 913369016</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-08-11 07:50:20 +1000" MODIFIED_BY="Narelle Willis">
<UP_TO_DATE>
<DATE DAY="26" MONTH="11" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="11" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="5" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="8" YEAR="2016"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2015-07-06 15:47:13 +1000" MODIFIED_BY="[Empty name]"/>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2015-11-30 15:21:15 +1100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2015-11-30 15:21:15 +1100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-11-30 15:21:15 +1100" MODIFIED_BY="[Empty name]">
<NAME>None known</NAME>
<COUNTRY CODE="PE">Peru</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-08-11 07:51:19 +1000" MODIFIED_BY="Narelle S Willis">
<SUMMARY MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<TITLE MODIFIED="2015-03-29 06:40:56 +1100" MODIFIED_BY="[Empty name]">Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units</TITLE>
<SUMMARY_BODY MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<P>
<B>What is the issue?</B>
</P>
<P>The hepatitis C virus (HCV) is easily transmitted intravenously, such as blood transfusions and the use of haemodialysis. It can cause a persistent infection and chronic liver disease. The frequency of HCV is higher among people on haemodialysis than the general population; and is associated with increased risk of death from heart disease and liver. We wanted to find out if the isolation of people with HCV during haemodialysis (using a different room, machines or dedicated staff, a specific shift) was effective in limiting the direct or indirect transmission of the virus to non-infected patients.</P>
<P>
<B>What did we do?</B>
</P>
<P>We conducted an extensive literature search to November 26, 2015, but only found one study looking at isolation as a strategy for controlling the transmission of HCV infection.</P>
<P>
<B>What did we find?</B>
</P>
<P>This one study included 12 centres (593 patients). Four centres assigned HCV-infected patients to a dedicated haemodialysis machine and eight centres did not. This study reported the incidence of HCV in haemodialysis patients decreased with the use of dedicated machines; however it was not possible to determine the benefits and harms associated with isolation, cost, or mortality from the disease.</P>
<P>
<B>Conclusions</B>
</P>
<P>There is insufficient evidence, but additional studies would help clarify the role of isolation to reduce the transmission of HCV in haemodialysis patients.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-08-11 07:51:19 +1000" MODIFIED_BY="Narelle S Willis">
<ABS_BACKGROUND MODIFIED="2016-07-04 18:07:05 +1000" MODIFIED_BY="Narelle Willis">
<P>The hepatitis C virus (HCV) infection affects about 2% of the world's population and can cause chronic liver infection and persistent long-term sequelae such as cirrhosis and liver cancer.</P>
<P>The prevalence of HCV infection among people on haemodialysis is often higher than the general population. The virus is easily transmitted parenterally, and blood transfusions have previously played a significant role in transmission; however, erythropoietin therapy has reduced the need for transfusions, and coupled with improved screening of donated blood, has significantly decreased transmission by transfusion. Although control of hospital-acquired infection has improved with the advent of biosafety measures, stopping HCV transmission in haemodialysis units remains challenging.</P>
<P>Isolating people infected with HCV involves physical separation from others to limit direct or indirect transmission and includes a number of strategies during dialysis. The evidence for isolating people infected with HCV during haemodialysis is sparse with some inconsistencies.<BR/>
</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-03-26 12:03:50 +1100" MODIFIED_BY="[Empty name]">
<P>To evaluate the benefits and harms of isolation of HCV-infected patients during haemodialysis on the transmission of HCV to other patients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<P>We searched the Cochrane Kidney and Transplant Specialised Register to 26 November 2015 through contact with the Information Specialist using search terms relevant to this review. We also searched the Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to 2015), Web of Science Conference Proceedings Citation Index-Science (CPCI-S, 1990 to 2015), ProQuest Dissertations &amp; Theses Database (1990 to 2015), and Open Grey (1990 to 2015).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-07-04 18:03:23 +1000" MODIFIED_BY="Narelle Willis">
<P>We included randomised controlled trials (RCTs), quasi-RCTs and cluster RCTs evaluating the clinical benefits and harms of isolating HCV-infected patients during haemodialysis on the transmission of HCV to other patients. We considered incidence of dialysis-acquired HCV infection, all-cause mortality, and adverse effects associated with isolation as the primary outcomes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-08-04 08:22:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) or standardised mean difference (SMD) and 95% CI for continuous outcomes.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-08-04 13:23:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>Only one study, which included 12 centres was identified: four centres used dedicated haemodialysis machines for HCV-infected patients and eight centres used non-dedicated machines. The total number of patients enrolled was 593. One centre was excluded after randomisation. Random sequence generation was not described and allocation concealment was not performed. Participants and personnel were not blinded and blinding of outcome assessors was not reported. Only 74.5% of the patients were followed for 9 months; and 47.3% were followed for an additional 9 months. The authors only reported one outcome, measuring the difference in the incidence of HCV in both groups. The authors did not consider the exposure time, to determine the adjusted rate of seroconversion risk/patient-year.<BR/>
<BR/>The study reported that the incidence of HCV infection during the first follow-up period (9 months) was 1.6% in the dedicated group, and 4.7% in the non-dedicated one (446 patients analysed out of 593 randomised; RR 0.34, 95% CI 0.11 to 1.07). During the second follow-up period (18 months) the incidence was 1.3% in the dedicated group and 5.8% in the control (281 patients analysed out of 593 randomised; RR 0.22, 95% CI 0.05 to 1.02). Therefore, we found no differences in terms of the number of participants developing HCV infection when comparing the dedicated group with the usual care. Moreover, the evidence was of very low quality, which means that we have very little confidence in the effect estimate.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-08-11 07:51:19 +1000" MODIFIED_BY="Narelle S Willis">
<P>The benefits and harms of isolation of HCV-infected patients during haemodialysis on the transmission of HCV to other patients are uncertain. Evidence from one short-duration cluster-randomised study with a high risk of bias did not find differences in terms of the number of participants developing HCV infection when comparing the use of dedicated haemodialysis machines for HCV infected patients with the use of non-dedicated machines.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<BACKGROUND MODIFIED="2016-08-04 13:24:29 +1000" MODIFIED_BY="Narelle S Willis">
<CONDITION MODIFIED="2016-08-04 13:24:16 +1000" MODIFIED_BY="Narelle S Willis">
<P>Hepatitis C virus (HCV) infection affects approximately 3% of the global population, or about 170 million people (<LINK REF="REF-Lee-2014" TYPE="REFERENCE">Lee 2014</LINK>). HCV causes persistent infection and chronic liver disease; long-term sequelae include cirrhosis (30%) and liver cancer (1% to 5%) (<LINK REF="REF-Hsu-2015" TYPE="REFERENCE">Hsu 2015</LINK>; <LINK REF="REF-Webster-2015" TYPE="REFERENCE">Webster 2015</LINK>).</P>
<P>Extrahepatic manifestations of chronic HCV infection are considered to be of immunologic origin and include cryoglobulinaemia, membranoproliferative glomerulonephritis, (<LINK REF="REF-Morales-2012" TYPE="REFERENCE">Morales 2012</LINK>) and porphyria cutanea tarda.</P>
<P>Prevalence of HCV infection in haemodialysis patients is usually higher than in the general population (<LINK REF="REF-Fabrizi-2012" TYPE="REFERENCE">Fabrizi 2012</LINK>). The overall incidence rate of HCV infection is 1.47/100 patient-years; 4.44/100 patient-years in low- to middle-income countries, and 0.99/100 patient-years in high-income countries (<LINK REF="REF-Su-2013" TYPE="REFERENCE">Su 2013</LINK>). Prevalence ranges from less than 5% in most Northern European countries (<LINK REF="REF-Fissell-2004" TYPE="REFERENCE">Fissell 2004</LINK>; <LINK REF="REF-Schneeberger-2000" TYPE="REFERENCE">Schneeberger 2000</LINK>) to over 70% in many parts of the world, including countries in Asia, Latin America and North Africa (<LINK REF="REF-Sun-2009" TYPE="REFERENCE">Sun 2009</LINK>; <LINK REF="REF-Vladutiu-2000" TYPE="REFERENCE">Vladutiu 2000</LINK>). However, the prevalence of HCV in European dialysis centres declined sharply in the early 2000s. This was attributed to reduced risk of hospital-acquired infection and occupational HCV infection (<LINK REF="REF-Jadoul-2004" TYPE="REFERENCE">Jadoul 2004</LINK>), increased mortality rates, and stabilisation of the incidence of acute HCV infection (<LINK REF="REF-Espinosa-2004" TYPE="REFERENCE">Espinosa 2004</LINK>). Falling prevalence rates emphasise the importance of adhering to recommended infection control precautions and virological follow-up to detect anti-HCV antibodies using sensitive, specific new-generation serological tests (<LINK REF="REF-Saune-2011" TYPE="REFERENCE">Saune 2011</LINK>).<BR/>
</P>
<P>HCV-infected haemodialysis patients are at increased risk of liver or cardiovascular disease-related death compared with non-infected patients (<LINK REF="REF-Fabrizi-2012" TYPE="REFERENCE">Fabrizi 2012</LINK>). HCV infection is associated with increased morbidity and mortality in kidney transplant recipients (<LINK REF="REF-Batty-2001" TYPE="REFERENCE">Batty 2001</LINK>; <LINK REF="REF-Butt-2007" TYPE="REFERENCE">Butt 2007</LINK>; <LINK REF="REF-Mahmoud-2004" TYPE="REFERENCE">Mahmoud 2004</LINK>). Anti-HCV-positive patients on dialysis are at increased risk compared with anti-HCV-negative patients.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-11-30 09:14:09 +1100" MODIFIED_BY="[Empty name]">
<P>Isolating HCV-infected patients (or patients waiting HCV screening results) during haemodialysis is defined as physical segregation from others for the express purpose of limiting direct or indirect transmission of HCV. Isolation policies may include strategies for HCV-infected patients with different grades of intensity, such as use of a dedicated dialysis machine, personnel, room, or shift, or other barrier precautions (such as aprons, gowns, or gloves), by healthcare professionals attending these patients. These strategies may be implemented in combination.</P>
</INTERVENTION>
<THEORY MODIFIED="2016-08-04 13:24:29 +1000" MODIFIED_BY="Narelle S Willis">
<P>HCV is easily transmitted parenterally and its control has therefore been a challenge in dialysis settings (<LINK REF="REF-Natov-2005" TYPE="REFERENCE">Natov 2005</LINK>; <LINK REF="REF-Su-2013" TYPE="REFERENCE">Su 2013</LINK>). More recently erythropoietin therapy, which reduces requirements for transfusions, together with more sensitive tests to detect HCV in donated blood, have significantly reduced transmission via transfusion (<LINK REF="REF-Marwaha-2014" TYPE="REFERENCE">Marwaha 2014</LINK>). The post-transfusion risk has been calculated at around 0.0001% in the USA (i.e. 1 blood transfusion in 1 million units of blood), with similar dramatic improvements in the viral safety of blood in other western countries (<LINK REF="REF-Selvarajah-2012" TYPE="REFERENCE">Selvarajah 2012</LINK>).</P>
<P>The WHO has estimated an overall prevalence of 3% for HCV infection in the global population, but there is a wide geographic variability: fewer than 5% of people in most northern European countries are infected, close to 10% in southern Europe and the USA, and estimates range from 10% to 50% and up to 70% in many low- to middle-income countries. HCV infection incidence has however decreased to less than 1.2% of people in high-income countries (<LINK REF="REF-Espinosa-2004" TYPE="REFERENCE">Espinosa 2004</LINK>; <LINK REF="REF-Finelli-2005" TYPE="REFERENCE">Finelli 2005</LINK>; <LINK REF="REF-Jadoul-2012" TYPE="REFERENCE">Jadoul 2012</LINK>).</P>
<P>This reduction was initially attributed to decreased rates of post-transfusion infection (<LINK REF="REF-Djordjevic-2000" TYPE="REFERENCE">Djordjevic 2000</LINK>; <LINK REF="REF-Valtuille-2002" TYPE="REFERENCE">Valtuille 2002</LINK>), but it was later ascribed to other infection control measures used to prevent hospital-acquired infection rates in dialysis units. Prevalence of HCV infection among people on haemodialysis is generally below 10% in most countries, but may be higher (&gt; 20%) where social crisis, war, or economic downturn exist (<LINK REF="REF-Ali-2011" TYPE="REFERENCE">Ali 2011</LINK>; <LINK REF="REF-Selm-2010" TYPE="REFERENCE">Selm 2010</LINK>; <LINK REF="REF-Voiculescu-2010" TYPE="REFERENCE">Voiculescu 2010</LINK>). In these situations, maintenance of chronic haemodialysis programs is highly challenging, and infection control programs are difficult to maintain.</P>
<P>In spite of reduced rates of infection, HCV transmission in haemodialysis units remains an unsolved problem. Despite advances in screening blood products for HCV people on haemodialysis it remains at a higher risk of infection than in the general population (<LINK REF="REF-Ozer-Etik-2015" TYPE="REFERENCE">Ozer Etik 2015</LINK>)</P>
<P>HCV seroconversion (change from anti-HCV negative to anti-HCV positive) has been detected in patients who were never transfused (<LINK REF="REF-Agarwal-2011" TYPE="REFERENCE">Agarwal 2011</LINK>) therefore other mechanisms of transmission occur in dialysis units. Shared haemodialysis machines (<LINK REF="REF-Elamin-2011" TYPE="REFERENCE">Elamin 2011</LINK>; <LINK REF="REF-Sartor-2004" TYPE="REFERENCE">Sartor 2004</LINK>) and reprocessing of dialysers from people with HCV have been linked to HCV transmission (<LINK REF="REF-Bashiri-2013" TYPE="REFERENCE">Bashiri 2013</LINK>). Other factors include physical proximity to an infected person and sharing personal items (<LINK REF="REF-Al_x002d_Ghamdi-2004" TYPE="REFERENCE">Al-Ghamdi 2004</LINK>; <LINK REF="REF-Fabrizi-2008" TYPE="REFERENCE">Fabrizi 2008</LINK>); breakdown in standard infection control practices, including improper handling and preparation of medications (<LINK REF="REF-Alter-2008" TYPE="REFERENCE">Alter 2008</LINK>; <LINK REF="REF-CDC-2009" TYPE="REFERENCE">CDC 2009</LINK>; <LINK REF="REF-Samandari-2005" TYPE="REFERENCE">Samandari 2005</LINK>; <LINK REF="REF-Thompson-2009" TYPE="REFERENCE">Thompson 2009</LINK>; <LINK REF="REF-Williams-2004" TYPE="REFERENCE">Williams 2004</LINK>); poor environmental cleaning (<LINK REF="REF-CDC-2009" TYPE="REFERENCE">CDC 2009</LINK>; <LINK REF="REF-Girou-2008" TYPE="REFERENCE">Girou 2008</LINK>; <LINK REF="REF-Kamili-2007" TYPE="REFERENCE">Kamili 2007</LINK>; <LINK REF="REF-Patel-2010" TYPE="REFERENCE">Patel 2010</LINK>; <LINK REF="REF-Thompson-2009" TYPE="REFERENCE">Thompson 2009</LINK>) and basic hygiene practices (<LINK REF="REF-Alfurayh-2000" TYPE="REFERENCE">Alfurayh 2000</LINK>; <LINK REF="REF-Patel-2010" TYPE="REFERENCE">Patel 2010</LINK>); staff numbers and workload (<LINK REF="REF-Arenas-2005" TYPE="REFERENCE">Arenas 2005</LINK>; <LINK REF="REF-CDC-2009" TYPE="REFERENCE">CDC 2009</LINK>; <LINK REF="REF-KDIGO-2008" TYPE="REFERENCE">KDIGO 2008</LINK>; <LINK REF="REF-Patel-2010" TYPE="REFERENCE">Patel 2010</LINK>; <LINK REF="REF-Shimokura-2011" TYPE="REFERENCE">Shimokura 2011</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-07-06 16:34:31 +1000" MODIFIED_BY="Narelle Willis">
<P>The evidence for or against the use of isolation of HCV-infected patients during haemodialysis is weak and certain inconsistencies exist regarding the recommendations for its use among different guidelines. The centres for Disease Control and Prevention (<LINK REF="REF-CDC-2001" TYPE="REFERENCE">CDC 2001</LINK>; <LINK REF="REF-Mbaeyi-2013" TYPE="REFERENCE">Mbaeyi 2013</LINK>) published guidelines to prevent the transmission of HCV and other infections among haemodialysis patients, but did not recommend the isolation of HCV-infected patients. <LINK REF="REF-KDIGO-2008" TYPE="REFERENCE">KDIGO 2008</LINK> stated that haemodialysis units should ensure implementation of and adherence to strict infection-control procedures designed to prevent transmission of blood-borne pathogens, including HCV, but isolation of HCV-infected patients was not recommended as an alternative to strict infection-control procedures (unless in cases of continued hospital-acquired transmission, where a local isolation policy may be deemed necessary). The UK Renal association stated that patients with HCV patients do not need to be dialysed in a segregated area, however more experienced staff should be assigned. If nosocomial transmission continues to occur, despite reinforcement and audit of the precautions, a local segregation policy may be deemed necessary (<LINK REF="REF-Geddes-2011" TYPE="REFERENCE">Geddes 2011</LINK>)</P>
<P>The European Best Practice (ERBP) Work Group considers that implementation of universal hygienic measures should be the standard of care. Isolation of positive patients could be considered, but only if this practice does not have a negative impact on the implementation and reinforcement of basic hygienic measures in the unit as a whole (<LINK REF="REF-Covic-2009" TYPE="REFERENCE">Covic 2009</LINK>). Some investigators support isolating patients with HCV infection in a specific haemodialysis room (<LINK REF="REF-Fabrizi-2008" TYPE="REFERENCE">Fabrizi 2008</LINK>), or suggest that the no isolation policy should not be generalised. Whether or not HCV-positive patients should be isolated is still debated, particularly since isolation policies to control HCV infection transmission in haemodialysis units involves significant logistic problems that should be considered.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-07-04 15:01:07 +1000" MODIFIED_BY="Narelle Willis">
<P>This review aimed to evaluate the benefits and harms of isolation of HCV-infected patients during haemodialysis on the transmission of HCV to other patients.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<SELECTION_CRITERIA MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<CRIT_STUDIES MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<P>All randomised controlled trials (RCTs) and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods), and cluster RCTs and cluster quasi-RCTs (where centres rather than individual patients were randomised), looking at isolation of HCV-infected patients during haemodialysis were eligible for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-07-04 15:01:32 +1000" MODIFIED_BY="Narelle Willis">
<P>All patients (adults and children) undergoing maintenance haemodialysis and dialysed in a haemodialysis centre (e.g. hospital unit, outpatient clinic) were eligible for inclusion.<B>
<BR/>
</B>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-07-04 15:01:32 +1000" MODIFIED_BY="Narelle Willis">
<SUBSECTION>
<HEADING LEVEL="4">Intervention group</HEADING>
<P>Any strategy targeting the isolation during haemodialysis of HCV-infected patients or patients waiting HCV screening results was eligible. Isolation was defined as the physical segregation of these patients from others with the express purpose of limiting direct or indirect transmission of HCV to other patients. Isolation policies could include a number of strategies with different grades of intensity, such as the use of a dedicated dialysis machine, personnel, room or dialysis shift.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control group</HEADING>
<P>We considered any control group that enabled comparison to determine the relative effect of the isolation strategy as eligible for inclusion. Studies comparing two types of isolation strategies were also eligible.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-07-04 15:10:22 +1000" MODIFIED_BY="Narelle Willis">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-07-04 15:10:22 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Incidence of dialysis-acquired HCV infection</LI>
<LI>All-cause mortality</LI>
<LI>Adverse effects associated to the isolation strategy (such as negative effects on patient mental well-being, or adverse effects related to supportive care failures).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-04-13 15:11:03 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Incidence of dialysis-acquired non-HCV infections</LI>
<LI>Patient satisfaction with treatment, measured with a validated tool</LI>
<LI>Isolation costs.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-08-04 13:25:59 +1000" MODIFIED_BY="Narelle S Willis">
<ELECTRONIC_SEARCHES MODIFIED="2016-08-04 13:25:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>We searched Cochrane Kidney and Transplant's Specialised Register to 26 November 2015 through contact with the Information Specialist using search terms relevant to this review. The Cochrane Kidney and Transplant Specialised Register contains studies identified from the following sources.</P>
<OL>
<LI>Monthly searches of the Cochrane Central Register of Controlled Trials CENTRAL</LI>
<LI>Weekly searches of MEDLINE OVID SP</LI>
<LI>Handsearching of kidney-related journals and the proceedings of major kidney conferences</LI>
<LI>Searching of the current year of EMBASE OVID SP</LI>
<LI>Weekly current awareness alerts for selected kidney journals</LI>
<LI>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</LI>
</OL>
<P>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on Cochrane Kidney and Transplant scope. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts are available in the Specialised Register section of information about the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Kidney and Transplant</A>.</P>
<P>We searched the following electronic databases.</P>
<OL>
<LI>Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to 2015)</LI>
<LI>Web of Science Conference Proceedings Citation Index-Science (CPCI-S, 1990 to 2015) (accessed via ISI Web of Science)</LI>
<LI>
<A HREF="http://www.proquest.com/">ProQuest Dissertations &amp; Theses Database</A> (1990 to 2015)</LI>
<LI>
<A HREF="http://www.opengrey.eu/">Open Grey</A> (1990 to 2015).</LI>
</OL>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used in strategies for this review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-07-06 16:51:06 +1000" MODIFIED_BY="Narelle Willis">
<OL>
<LI>Reference lists of review articles and relevant studies and clinical practice guidelines.</LI>
<LI>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<STUDY_SELECTION MODIFIED="2016-07-06 16:51:18 +1000" MODIFIED_BY="Narelle Willis">
<P>The search strategy described was used to obtain titles and abstracts of studies that may be relevant to the review. Titles and abstracts were screened independently by two authors, who discarded studies that were not applicable; however, studies and reviews thought to include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts, and if necessary the full text, of these studies to determine which satisfied the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-04-13 15:02:26 +1000" MODIFIED_BY="[Empty name]">
<P>Data extraction was to be carried out independently by two authors using standard data extraction forms. Studies reported in non-English language journals were to be translated before assessment. Where more than one publication of one study existed, reports were to be grouped together and the publication with the most complete data used in analyses. Where relevant outcomes were only published in earlier versions these data were to be used. Any discrepancy between published versions was to be highlighted.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<P>The following items were to be independently assessed by two authors using the risk of bias assessment tool (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>) (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<UL>
<LI>Was there adequate sequence generation (selection bias)?</LI>
<LI>Was allocation adequately concealed (selection bias)?</LI>
<LI>Was recruitment bias adequately prevented?</LI>
<LI>Were baseline imbalances (in terms of either the clusters or the individuals) adequately addressed?</LI>
<LI>Was knowledge of the allocated interventions adequately prevented during the study?</LI>
<UL>
<LI>Participants and personnel (performance bias)</LI>
<LI>Outcome assessors (detection bias)</LI>
</UL>
<LI>Were incomplete outcome data adequately addressed (attrition bias)?</LI>
<LI>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?</LI>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
<LI>Was the study analysed by correct statistical methods (i.e. taking the clustering into account)?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-05-17 16:46:51 +1000" MODIFIED_BY="Ann Jones">
<P>For dichotomous data and for counts of rare events and rates (dialysis-acquired HCV infections, dialysis-acquired non-HCV infections, mortality due to dialysis-acquired infections, all-cause mortality, adverse effects) we planned to report risk ratios (RR); for continuous data (patient satisfaction with treatment) we planned to use the mean difference (MD) with 95% CI. Where different scales were used to measure continuous outcomes, we planned to calculate a standardised mean difference (SMD).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-04-13 15:11:18 +1000" MODIFIED_BY="[Empty name]">
<P>We planned to include cluster RCTs, and when possible, extract effect measures and standard error rates from an analysis taking clustering into account. If that was not possible, we planned to extract the number of clusters and estimate the intra-cluster correlation coefficient to inform a reliable analysis. If this was not possible, we planned to disregard the clustering and investigate the effect of this in a sensitivity analysis (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). </P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-04-13 14:48:39 +1000" MODIFIED_BY="[Empty name]">
<P>We planned to extract data for intention-to-treat analyses (ITT) and contact authors if required information was missing. Where ITT analysis was not possible, we planned to extract data from an available case analysis and assess the risk of bias from attrition.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-04-13 14:48:44 +1000" MODIFIED_BY="[Empty name]">
<P>We planned to analyse heterogeneity using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance, and the I² statistic.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-03-29 05:32:27 +1100" MODIFIED_BY="[Empty name]">
<P>We did not expect that a sufficient number of studies would be identified to create a useful funnel plot. Assessing reporting bias is difficult, but we planned to note whether outcomes that we considered important were reported. We planned to contact authors about possible unpublished outcomes.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-04-13 14:49:20 +1000" MODIFIED_BY="[Empty name]">
<P>We planned to use a random-effects model and to express the results as both relative risks and number-needed-to-screen to achieve the relevant outcomes, both beneficial and harmful.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-07-04 15:01:34 +1000" MODIFIED_BY="Narelle Willis">
<P>We planned to perform the subgroup analyses</P>
<OL>
<LI>Mean duration of the haemodialysis treatment</LI>
<LI>The degree of missing primary outcome data</LI>
<OL>
<LI>High prevalence of HCV in the haemodialysis unit: studies implemented in a context of high HCV prevalence (&lt; 5%) versus non-high HCV prevalence (&#8805; 5%)</LI>
</OL>
<LI>Outbreak situation: studies implemented when healthcare associated infection (any pathogen) were noted to be increasing or to exceed a recognised benchmark versus non outbreak situation</LI>
<LI>Types of isolation.</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-07-04 13:38:04 +1000" MODIFIED_BY="Narelle Willis">
<P>We planned to perform sensitivity analyses to explore the influence of the following factors on effect size.</P>
<UL>
<LI>Repeating the meta-analysis to assess the effect of excluding studies with high risk of bias</LI>
<LI>Exploring the impact of the assumptions taken in the available case analysis by performing a sensitivity analysis with imputation of missing data</LI>
<LI>Assessing the effect of the statistical model chosen for meta-analysis (fixed-effect model versus random-effects model)</LI>
<LI>Repeating the meta-analysis to assess the effect of including only studies with allocation to interventions at the group level (cluster designs) (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</LI>
</UL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<STUDY_DESCRIPTION MODIFIED="2016-08-04 11:40:41 +1000" MODIFIED_BY="Narelle S Willis">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2016-08-04 11:36:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>The combined search of MEDLINE, EMBASE and CENTRAL identified a total of 126 articles, of which 125 were excluded.</P>
<OL>
<LI>Twenty one records were duplicates</LI>
<LI>After reviewing the abstracts, 93 records were excluded because they did not meet our inclusion criteria</LI>
<LI>After full text review an additional 11 records, which were not RCTs, were excluded.</LI>
</OL>
<P>We therefore included one study enrolling 593 patients (<LINK REF="STD-Shamshirsaz-2004" TYPE="STUDY">Shamshirsaz 2004</LINK>). A flow chart of the study selection process is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-08-04 11:40:41 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<LINK REF="STD-Shamshirsaz-2004" TYPE="STUDY">Shamshirsaz 2004</LINK> was a prospective RCT evaluating the effect of dialysis machine separation in reducing HCV transmission to haemodialysis patients. Selected centres were randomly divided into dedicated and non-dedicated haemodialysis machine groups. Positive cases were confirmed by RT-PCR. Information regarding age, sex, occupation (health care personnel, surgeons and dentists), HCV-infected relatives, previous peritoneal dialysis, surgery during last 2 months, duration of haemodialysis, number of blood product transfusions, history of organ transplantation, and the causes of ESRD was collected. Outcomes included incidence of HCV infection in both groups.</P>
<P>Patients were dialyzed for 4 to 4.5 hours, 2 or 3 times/week, using standard haemodialysis techniques. All included haemodialysis patients were HIV and hepatitis B surface antigen (HBsAg) negative. Dialysis membranes were low pressure and used only once and haemodialysis machines were bleached and rinsed between dialysis sessions according to the manufacturers' instruction. All machines were located in dialysis wards and not in separate rooms for both groups. Patient to staff ratio in the dedicated and non-dedicated groups was not statistically different (3.1 and 3.4 respectively) and all staff members were negative for anti-HCV. Education courses hygiene guidelines the CDC were conducted for all personnel involved in patient care, a checklist of the practice was used. In all centres the patients had specific dialysis place. It was specified how often the tests were performed HCV patients during the study or whether this was routinely carried out.</P>
<P>The patients were followed for 9 months (first follow-up population) and 281 patients who remained within the study were followed for an additional 9 months (second follow-up population). See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-07-04 14:09:22 +1000" MODIFIED_BY="Narelle Willis">
<P>Eleven studies were not RCTs (<LINK REF="STD-Agarwal-2009" TYPE="STUDY">Agarwal 2009</LINK>; <LINK REF="STD-Barril-2003" TYPE="STUDY">Barril 2003</LINK>; <LINK REF="STD-Gallego-2006" TYPE="STUDY">Gallego 2006</LINK>; <LINK REF="STD-Garcia_x002d_Valdecasas-1994" TYPE="STUDY">Garcia-Valdecasas 1994</LINK>; <LINK REF="STD-Huang-1995" TYPE="STUDY">Huang 1995</LINK>; <LINK REF="STD-Mohamed-2010" TYPE="STUDY">Mohamed 2010</LINK>; <LINK REF="STD-Ross-2009" TYPE="STUDY">Ross 2009</LINK>; <LINK REF="STD-Saxena-2003" TYPE="STUDY">Saxena 2003</LINK>; <LINK REF="STD-Shebeb-2006" TYPE="STUDY">Shebeb 2006</LINK>; <LINK REF="STD-Valtuille-1998" TYPE="STUDY">Valtuille 1998</LINK>; <LINK REF="STD-Yang-2003" TYPE="STUDY">Yang 2003</LINK>)</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<P>See risk of bias in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2016-07-04 15:16:19 +1000" MODIFIED_BY="Narelle Willis">
<P>This study did not describe the use of a random number table to generate the allocation sequence. Allocation concealment was not performed</P>
<P>Randomisation was performed by dialysis centre. It was a cluster RCT, which included four centres (dedicated) compared with eight centres (non-dedicated).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-07-04 15:16:58 +1000" MODIFIED_BY="Narelle Willis">
<P>Participants (patients and investigators) were not blinded. Blinding of outcome assessors was not reported.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-08-04 10:46:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>Only 74.5% (446/593) of the patients were followed for 9 months, and 47.3% (281/593) were followed for an additional 9 months.</P>
<P>One centre was excluded after randomisation causing a deviation from protocol.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<P>The authors only reported one outcome, measuring the difference in the incidence of HCV in both groups. No secondary outcomes were reported.</P>
<P>The authors did not consider the exposure time, to determine the adjusted rate of seroconversion risk/patient-year.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-08-04 10:12:56 +1000" MODIFIED_BY="Narelle S Willis">
<P>The assessments of the risk of bias domains relative to cluster designs are detailed in the risk of bias table (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-08-09 13:59:12 +1000" MODIFIED_BY="Narelle Willis">
<SUBSECTION>
<HEADING LEVEL="3">Incidence of dialysis-acquired HCV infection</HEADING>
<P>
<LINK REF="STD-Shamshirsaz-2004" TYPE="STUDY">Shamshirsaz 2004</LINK> reported the incidence of HCV infection was 1.6% in the dedicated group and 4.7% in the non-dedicated one (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (1 study 446 participants): RR 0.34, 95% CI 0.11 to 1.07) during the first follow-up period (9 months). During the second follow-up period (18 months), the incidence was 1.3% in the dedicated group and 5.8% in the non-dedicated group (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> (1 study, 281 participants): RR 0.22, 95% CI 0.05 to 1.02). Therefore, we found no differences in terms of the number of participants developing HCV infection when comparing the dedicated group with the usual care. Moreover, the evidence was of very low quality, which means that we have very little confidence in the effect estimate and that the true effect is likely to be substantially different from the estimate of effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">All-cause mortality</HEADING>
<P>Mortality was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>Adverse effects associated with the isolation strategy were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Incidence of dialysis-acquired non-HCV infections</HEADING>
<P>Incidence of dialysis-acquired non-HCV infections were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Patient satisfaction with treatment</HEADING>
<P>Patient satisfaction with treatment was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Isolation costs</HEADING>
<P>Isolation costs were not reported.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-08-04 10:59:00 +1000" MODIFIED_BY="Narelle S Willis">
<SUMMARY_OF_RESULTS MODIFIED="2016-08-04 10:59:00 +1000" MODIFIED_BY="Narelle S Willis">
<P>Only one study meeting our inclusion criteria was identified (<LINK REF="STD-Shamshirsaz-2004" TYPE="STUDY">Shamshirsaz 2004</LINK>). This study selected haemodialysis centres, one by one to reach a total number of 593 patients (12 centres). Selected centres were randomly divided in to dedicated and non-dedicated haemodialysis machine groups, including 297 patients in the dedicated group (4 centres) and 296 patients in the non-dedicated group (8 centres). This study found that the use of dialysis machines dedicated for HCV infected individuals, as compared with the use of non-dedicated dialysis machines, made no difference in terms of reducing the incidence incidence of HCV infection during the first (9 months) or second (18 months) follow-up periods. The quality of the evidence was very low (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>This study did not report any of our other primary outcomes of interest (all-cause mortality, adverse effects associated with the strategy of isolation).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-07-04 15:34:06 +1000" MODIFIED_BY="Narelle Willis">
<P>We planned to include patients (adults and children) undergoing maintenance haemodialysis and dialysed in a haemodialysis centre and assess whether strategies isolation machine, room, staff or dialysis shift influence the transmission of hepatitis C. Our search just found one study where the separation of machines is evaluated as a form of isolation.</P>
<P>Consideration should also be given to both the prevalence of hepatitis C and the geographical region as this may influence the possibility of seroconversion. Regions with high prevalence may require isolation combined strategies: room, machine, and personnel. No costs are included for the isolation strategy.</P>
<P>Methods of randomisation were unclear, participants and patients were not blinded, so that the results of this study must be considered with some caution. Confirmatory research is required. Any further studies conducted in this area must be well designed RCTs assessing these primary outcomes.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-08-04 10:58:30 +1000" MODIFIED_BY="Narelle S Willis">
<P>This review is based on the evidence of one RCT (<LINK REF="STD-Shamshirsaz-2004" TYPE="STUDY">Shamshirsaz 2004</LINK>) that included a total of 12 haemodialysis centres (593 patients) divided into a group of dedicated dialysis machines involving four centres: 297 patients, 267 negative and 30 positive for HCV and a group of centres with non-dedicated machines: 8 centres: 296 patients, 275 negative and 21 positive for HCV.</P>
<P>The authors did not disclose the details of the method of randomisation, participants and patients were not blinded, and blinding of outcome assessors was not reported. The authors decided to exclude, after randomisation, one of dialysis centres in the non-dedicated group due to non-adherence to CDC hygienic guidelines early in the study. There was a high risk of bias due to incomplete outcome data: only 74.5% of patients were followed for 9 months, and 47.3% were followed for an additional 9 months. In addition, the estimation of the effect of the intervention was imprecise. This makes the quality of evidence very low (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-07-04 15:47:06 +1000" MODIFIED_BY="Narelle Willis">
<P>We followed the Cochrane Collaboration guidelines for conducting this systematic review and meta-analysis. Strengths of our review include the searching of several databases. Study selection, assessment of risk of bias, and data extraction were performed by two authors, which reduced the risk of error and bias. Although efforts were made to collect relevant data, the possibility of missing data cannot be excluded. Publication bias remains a possible source of important bias. Meanwhile, interpretation of the result should be done with extreme caution.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-07-04 17:58:35 +1000" MODIFIED_BY="Narelle Willis">
<P>We are not aware of any other systematic review on this topic; many authors have reported some reduction (but not full prevention) of HCV transmission in haemodialysis, and after the adoption of an isolation policy, most of the studies have compared their results with their own historical control (before-and-after). Thus, it is unclear whether the reported improvement resulted from the adoption of an isolation policy or rather from the simultaneous raising of awareness and reinforcement of the application of hygienic precautions. These isolation policies include: implementing the isolation of a room (<LINK REF="STD-Agarwal-2009" TYPE="STUDY">Agarwal 2009</LINK>; <LINK REF="STD-Barril-2003" TYPE="STUDY">Barril 2003</LINK>); using exclusive machines (<LINK REF="STD-Garcia_x002d_Valdecasas-1994" TYPE="STUDY">Garcia-Valdecasas 1994</LINK>); and isolating machines, room and staff (<LINK REF="STD-Gallego-2006" TYPE="STUDY">Gallego 2006</LINK>; <LINK REF="STD-Huang-1995" TYPE="STUDY">Huang 1995</LINK>; <LINK REF="STD-Saxena-2003" TYPE="STUDY">Saxena 2003</LINK>); and <LINK REF="STD-Mohamed-2010" TYPE="STUDY">Mohamed 2010</LINK>, <LINK REF="STD-Ross-2009" TYPE="STUDY">Ross 2009</LINK> and <LINK REF="STD-Shebeb-2006" TYPE="STUDY">Shebeb 2006</LINK>, compared isolation versus universal precautions. In all cases isolation was found to decrease the rate of seroconversion. In addition, <LINK REF="STD-Yang-2003" TYPE="STUDY">Yang 2003</LINK> conducted a study with three sets of patients: one set without isolation, a second set with a dedicated area and a dedicated machine in the same room and a third set of patients isolated in a separate room, and showed that isolation in a different room was better than dedicated machines.</P>
<P>In contrast, a DOPPS multicentre study concluded that isolation does not protect against transmission of HCV in haemodialysis patients (<LINK REF="REF-Fissell-2004" TYPE="REFERENCE">Fissell 2004</LINK>). A prospective observational study by <LINK REF="REF-Jadoul-1998" TYPE="REFERENCE">Jadoul 1998</LINK> showed a reduction from 1.4% to 0% of the annual incidence of HCV seroconversion. They have reported a reduction of HCV transmission after the reinforcement of basic hygienic precautions, without any isolation measures.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-08-04 10:57:47 +1000" MODIFIED_BY="Narelle S Willis">
<IMPLICATIONS_PRACTICE MODIFIED="2016-07-04 15:01:37 +1000" MODIFIED_BY="Narelle Willis">
<P>Data from robust RCTs are not available to allow conclusions to be drawn about the relative effectiveness of isolation as a strategy to control HCV transmission in haemodialysis units. Therefore, the benefits and harms of isolation remain unknown.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-08-04 10:57:47 +1000" MODIFIED_BY="Narelle S Willis">
<P>Large, multicentre long-term RCTs of good quality are required to answer the questions concerning the benefits and harms of isolation of HCV-infected patients during haemodialysis. These studies should evaluate mortality, costs and complications associated with isolation. These studies should ensure the physical separation of either the centre or room; these programs should have strict isolation strategies in place that include staff as well as machines dedicated to HCV-infected haemodialysis patients.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-08-04 11:29:53 +1000" MODIFIED_BY="Narelle S Willis">
<P>We wish to acknowledge the Cochrane Kidney and Transplant editorial team and the referees for the comments and feedback during the preparation of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-04-13 12:15:53 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Jessica I Bravo Zuñiga: none known</LI>
<LI>César Loza Munárriz: none known</LI>
<LI>Jesús López-Alcalde: none known</LI>
</UL>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-03-26 14:12:34 +1100" MODIFIED_BY="[Empty name]">
<P>Writing of protocol and review: JB, CLM, JLA<BR/>Screening of titles and abstracts: JB, CLM, JLA<BR/>Assessment for inclusion: JB, CLM, JLA<BR/>Quality assessment: JB, CLM, JLA<BR/>Data extraction: JB, CLM<BR/>Data entry into RevMan: JB, CLM<BR/>Data analysis: JB, CLM, JLA</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-08-04 13:37:56 +1000" MODIFIED_BY="Narelle S Willis">
<P>Additional risk of bias assessments have been added due to the inclusion of cluster RCTs.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-08-10 22:53:33 +0100" MODIFIED_BY="Narelle Willis">
<STUDIES MODIFIED="2016-07-04 11:46:18 +1000" MODIFIED_BY="Narelle Willis">
<INCLUDED_STUDIES MODIFIED="2016-02-23 12:59:21 +1100" MODIFIED_BY="Gail Y Higgins">
<STUDY DATA_SOURCE="PUB" ID="STD-Shamshirsaz-2004" MODIFIED="2016-02-23 12:59:21 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Shamshirsaz 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-02-23 12:59:21 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shamshirsaz AA, Kamgar M, Bekheirnia MR, Ayazi F, Hashemi SR, Bouzari N, et al</AU>
<TI>The role of hemodialysis machines dedication in reducing hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study</TI>
<SO>BMC Nephrology</SO>
<YR>2004</YR>
<VL>5</VL>
<PG>13</PG>
<IDENTIFIERS MODIFIED="2016-02-23 12:59:03 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4350841"/><IDENTIFIER MODIFIED="2016-02-23 12:59:03 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="15469615"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4350840"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-07-04 11:46:18 +1000" MODIFIED_BY="Narelle Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Agarwal-2009" MODIFIED="2014-11-11 03:15:15 +1100" MODIFIED_BY="[Empty name]" NAME="Agarwal 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-11-11 03:15:15 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agarwal SK, Dash SC, Gupta S, Pandey RM</AU>
<TI>Hepatitis C virus infection in haemodialysis: the 'no-isolation' policy should not be generalized</TI>
<SO>Nephron</SO>
<YR>2009</YR>
<VL>111</VL>
<NO>2</NO>
<PG>c133-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4350843"/><IDENTIFIER TYPE="MEDLINE" VALUE="19147995"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4350842"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barril-2003" MODIFIED="2014-11-11 03:45:00 +1100" MODIFIED_BY="[Empty name]" NAME="Barril 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-11-11 03:45:00 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barril G, Traver JA</AU>
<TI>Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: effect of time, initiating HCV prevalence studies and adoption of isolation measures</TI>
<SO>Antiviral Research</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>2</NO>
<PG>129-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4350845"/><IDENTIFIER TYPE="MEDLINE" VALUE="14638409"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4350844"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallego-2006" MODIFIED="2015-04-09 10:38:59 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Gallego 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-04-09 10:38:59 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallego E, Lopez A, Perez J, Llamas F, Lorenzo I, Lopez E, et al</AU>
<TI>Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis</TI>
<SO>Nephron</SO>
<YR>2006</YR>
<VL>104</VL>
<NO>1</NO>
<PG>c1-6</PG>
<IDENTIFIERS MODIFIED="2015-04-09 10:38:56 +1000" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4350847"/><IDENTIFIER MODIFIED="2015-04-09 10:38:56 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="16685138"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4350846"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Valdecasas-1994" MODIFIED="2016-02-23 13:05:57 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Garcia-Valdecasas 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-02-23 13:05:57 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Valdecasas J, Bernal MC, et al</AU>
<TI>Efficacy of preventive measures to avoid the transmission of the hepatitis C virus in dialysis units [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>10</NO>
<PG>1506</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:05:57 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:05:57 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00261074"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4350849"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4350848"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-1995" MODIFIED="2015-04-09 10:30:44 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Huang 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-04-09 10:30:44 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Huang CC, Liaw JF, Fang JT, Lee CC, Chien HC</AU>
<TI>Prevention of hepatitis C viral infection in the dialysis unit: to reuse dialyzer or not? [abstract]</TI>
<SO>ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain</SO>
<YR>1995</YR>
<PG>522</PG>
<IDENTIFIERS MODIFIED="2015-04-09 10:30:44 +1000" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2015-04-09 10:30:44 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00509241"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4350851"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4350850"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohamed-2010" MODIFIED="2015-05-17 16:52:33 +1000" MODIFIED_BY="Ann Jones" NAME="Mohamed 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-05-17 16:52:33 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohamed, Waleed Z</AU>
<TI>Prevention of hepatitis C virus in hemodialysis patients: five years experience from a single center</TI>
<SO>Saudi Journal of Kidney Diseases &amp; Transplantation</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>3</NO>
<PG>548-54</PG>
<IDENTIFIERS MODIFIED="2015-04-09 10:39:53 +1000" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4350853"/><IDENTIFIER MODIFIED="2015-04-09 10:39:53 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="20427892"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4350852"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ross-2009" MODIFIED="2016-07-04 11:46:18 +1000" MODIFIED_BY="Narelle Willis" NAME="Ross 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-07-04 11:46:18 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ross RS, Viazov S, Clauberg R, Wolters B, Fengler I, Eveld K, et al</AU>
<TI>Lack of de novo hepatitis C virus infections and absence of nosocomial transmissions of GB virus C in a large cohort of German haemodialysis patients</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>4</NO>
<PG>230-8</PG>
<IDENTIFIERS MODIFIED="2015-04-09 10:40:36 +1000" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4350855"/><IDENTIFIER MODIFIED="2015-04-09 10:40:36 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="19175869"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4350854"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saxena-2003" MODIFIED="2014-11-11 04:05:53 +1100" MODIFIED_BY="[Empty name]" NAME="Saxena 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-11-11 04:05:53 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saxena AK, Panhotra BR, Sundaram DS, Naguib M, Venkateshappa CK, Uzzaman W, et al</AU>
<TI>Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the Middle East</TI>
<SO>American Journal of Infection Control</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>1</NO>
<PG>26-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4350857"/><IDENTIFIER TYPE="MEDLINE" VALUE="12548254"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4350856"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shebeb-2006" MODIFIED="2015-05-17 16:52:06 +1000" MODIFIED_BY="Ann Jones" NAME="Shebeb 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-05-17 16:52:06 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shebeb AM, Kotkat AM, Abd El Reheim SM, Farghaly AG, Fetohy EM</AU>
<TI>An intervention study for prevention of HCV infection in some hemodialysis units in Alexandria</TI>
<SO>Journal of the Egyptian Public Health Association</SO>
<YR>2006</YR>
<VL>81</VL>
<NO>1-2</NO>
<PG>119-41</PG>
<IDENTIFIERS MODIFIED="2015-04-09 10:42:07 +1000" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4350859"/><IDENTIFIER MODIFIED="2015-04-09 10:42:07 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="17382087"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4350858"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valtuille-1998" MODIFIED="2015-05-10 10:08:11 +1000" MODIFIED_BY="[Empty name]" NAME="Valtuille 1998" YEAR="1998 Oct">
<REFERENCE MODIFIED="2015-05-10 10:08:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valtuille R, Fernandez JL, Berridi J, Moretto H, del Pino N, Rendo P, et al</AU>
<TI>Evidence of hepatitis C virus passage across dialysis membrane</TI>
<SO>Nephron</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>2</NO>
<PG>194-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4350861"/><IDENTIFIER TYPE="MEDLINE" VALUE="9736819"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4350860"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2003" MODIFIED="2015-05-17 16:51:56 +1000" MODIFIED_BY="Ann Jones" NAME="Yang 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-05-17 16:51:56 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang CS, Chang HH, Chou CC, Peng SJ</AU>
<TI>Isolation effectively prevents the transmission of hepatitis C virus in the hemodialysis unit</TI>
<SO>Journal of the Formosan Medical Association</SO>
<YR>2003</YR>
<VL>102</VL>
<NO>2</NO>
<PG>79-85</PG>
<IDENTIFIERS MODIFIED="2015-04-09 10:42:43 +1000" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4350863"/><IDENTIFIER MODIFIED="2015-04-09 10:42:43 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="12709735"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4350862"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-05-24 08:58:54 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2014-11-11 03:45:45 +1100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-07-04 12:24:59 +1000" MODIFIED_BY="Narelle Willis">
<ADDITIONAL_REFERENCES MODIFIED="2016-07-04 12:18:57 +1000" MODIFIED_BY="Narelle Willis">
<REFERENCE ID="REF-Agarwal-2011" MODIFIED="2013-04-02 21:47:46 +1100" MODIFIED_BY="[Empty name]" NAME="Agarwal 2011" TYPE="JOURNAL_ARTICLE">
<AU>Agarwal SK</AU>
<TI>Hemodialysis of patients with HCV infection: isolation has a definite role</TI>
<SO>Nephron</SO>
<YR>2011</YR>
<VL>117</VL>
<NO>4</NO>
<PG>c328-32</PG>
<IDENTIFIERS MODIFIED="2013-04-02 21:47:46 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 21:47:46 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="21051906"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Al_x002d_Ghamdi-2004" MODIFIED="2016-07-04 11:50:35 +1000" MODIFIED_BY="Narelle Willis" NAME="Al-Ghamdi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Al-Ghamdi SM</AU>
<TI>Nurses' knowledge and practice in hemodialysis units: Comparison between nurses in units with high and low prevalence of hepatitis C virus infection</TI>
<SO>Saudi Journal of Kidney Diseases &amp; Transplantation</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>1</NO>
<PG>34-40</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:09:51 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:09:51 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="18202464"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alfurayh-2000" MODIFIED="2013-04-02 21:48:43 +1100" MODIFIED_BY="Leslee Edwards" NAME="Alfurayh 2000" TYPE="JOURNAL_ARTICLE">
<AU>Alfurayh O, Sabeel A, Al Ahdal MN, Almeshari K, Kessie G, Hamid M, et al</AU>
<TI>Hand contamination with hepatitis C virus in staff looking after hepatitis C positive hemodialysis patients</TI>
<SO>American Journal of Nephrology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>2</NO>
<PG>103-6</PG>
<IDENTIFIERS MODIFIED="2013-04-02 21:48:43 +1100" MODIFIED_BY="Narelle S Willis"><IDENTIFIER MODIFIED="2013-04-02 21:48:43 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10773609"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ali-2011" MODIFIED="2016-02-23 13:10:44 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Ali 2011" TYPE="JOURNAL_ARTICLE">
<AU>Ali I, Siddique L, Rehman LU, Khan NU, Iqbal A, Munir I, et al</AU>
<TI>Prevalence of HCV among the high risk groups in Khyber Pakhtunkhwa</TI>
<SO>Virology Journal</SO>
<YR>2011</YR>
<VL>8</VL>
<PG>296</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:10:44 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:10:44 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="21663685"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alter-2008" MODIFIED="2013-04-02 21:51:38 +1100" MODIFIED_BY="[Empty name]" NAME="Alter 2008" TYPE="OTHER">
<AU>Alter MJ</AU>
<TI>Healthcare should not be a vehicle for transmission of hepatitis C virus</TI>
<SO>Journal of Hepatology</SO>
<YR>2008</YR>
<VL>48</VL>
<NO>1</NO>
<PG>2-4</PG>
<IDENTIFIERS MODIFIED="2013-04-02 21:51:38 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 21:51:38 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18023493"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arenas-2005" MODIFIED="2013-04-02 21:52:18 +1100" MODIFIED_BY="[Empty name]" NAME="Arenas 2005" TYPE="JOURNAL_ARTICLE">
<AU>Arenas MD, Sanchez-Paya J, Barril G, Garcia-Valdecasas J, Gorriz JL, Soriano A, et al</AU>
<TI>A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>6</NO>
<PG>1164-71</PG>
<IDENTIFIERS MODIFIED="2013-04-02 21:52:18 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 21:52:18 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15769816"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bashiri-2013" MODIFIED="2016-02-23 13:11:51 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Bashiri 2013" TYPE="JOURNAL_ARTICLE">
<AU>Bashiri H, Omrani H, Mami M, Rezaee M</AU>
<TI>Comparison of contamination passing through Iranian and non- Iranian filters of ultra filtration dialysis machines in patients with hepatitis C</TI>
<SO>Hepatitis Monthly</SO>
<YR>2013</YR>
<VL>13</VL>
<NO>1</NO>
<PG>e5912</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:11:51 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:11:51 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="23483113"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Batty-2001" MODIFIED="2008-10-09 10:02:11 +1100" MODIFIED_BY="Leslee Edwards" NAME="Batty 2001" TYPE="JOURNAL_ARTICLE">
<AU>Batty DS Jr, Swanson SJ, Kirk AD, Ko CW, Agodoa LY, Abbott KC</AU>
<TI>Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival</TI>
<SO>American Journal of Transplantation</SO>
<YR>2001</YR>
<VL>1</VL>
<NO>2</NO>
<PG>179-84</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="12099367"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Butt-2007" MODIFIED="2013-04-02 21:56:15 +1100" MODIFIED_BY="[Empty name]" NAME="Butt 2007" TYPE="JOURNAL_ARTICLE">
<AU>Butt AA, Skanderson M, McGinnis KA, Ahuja T, Bryce CL, Barnato AE, et al</AU>
<TI>Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>10</NO>
<PG>688-96</PG>
<IDENTIFIERS MODIFIED="2013-04-02 21:56:11 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 21:56:11 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17875003"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CDC-2001" MODIFIED="2016-02-23 13:12:35 +1100" MODIFIED_BY="Gail Y Higgins" NAME="CDC 2001" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Recommendations for preventing transmission of infections among chronic hemodialysis patients</TI>
<SO>MMWR - Morbidity &amp; Mortality Weekly Report. Recommendations &amp; Reports</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>RR-5</NO>
<PG>1-43</PG>
<IDENTIFIERS MODIFIED="2013-04-02 21:59:06 +1100" MODIFIED_BY="Narelle S Willis"><IDENTIFIER MODIFIED="2013-04-02 21:59:06 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11349873"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CDC-2009" MODIFIED="2016-07-04 11:57:04 +1000" MODIFIED_BY="Narelle Willis" NAME="CDC 2009" TYPE="JOURNAL_ARTICLE">
<AU>Centers for Disease Control and Prevention (CDC)</AU>
<TI>Hepatitis C virus transmission at an outpatient hemodialysis unit--New York, 2001-2008</TI>
<SO>MMWR - Morbidity &amp; Mortality Weekly Report</SO>
<YR>2009</YR>
<VL>58</VL>
<NO>8</NO>
<PG>189-94</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:01:12 +1100" MODIFIED_BY="Narelle S Willis"><IDENTIFIER MODIFIED="2013-04-02 22:01:12 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19265779"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Covic-2009" MODIFIED="2016-02-23 13:13:13 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Covic 2009" TYPE="JOURNAL_ARTICLE">
<AU>Covic A, Abramowicz D, Bruchfeld A, Leroux-Roels G, Samuel D, van Biesen W, et al</AU>
<TI>Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>3</NO>
<PG>719-27</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:13:13 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:13:13 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="19202192"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2016-07-04 11:58:47 +1000" MODIFIED_BY="Narelle Willis" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JP, Altman DG</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Djordjevic-2000" MODIFIED="2013-04-02 22:15:32 +1100" MODIFIED_BY="Leslee Edwards" NAME="Djordjevic 2000" TYPE="JOURNAL_ARTICLE">
<AU>Djordjevic V, Stojanovic K, Stojanovic M, Stefanovic V</AU>
<TI>Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit. A prospective study</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>181-8</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:15:32 +1100" MODIFIED_BY="Narelle S Willis"><IDENTIFIER MODIFIED="2013-04-02 22:15:32 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10795663"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elamin-2011" MODIFIED="2016-07-04 11:59:56 +1000" MODIFIED_BY="Narelle Willis" NAME="Elamin 2011" TYPE="JOURNAL_ARTICLE">
<AU>Elamin S, Abu-Aisha H</AU>
<TI>Prevention of hepatitis B virus and hepatitis C virus transmission in hemodialysis centers: review of current international recommendations</TI>
<SO>Arab Journal of Nephrology and Transplantation</SO>
<YR>2011</YR>
<VL>4</VL>
<NO>1</NO>
<PG>35-47</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:13:51 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:13:51 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="21469594"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Espinosa-2004" MODIFIED="2013-04-02 22:17:06 +1100" MODIFIED_BY="[Empty name]" NAME="Espinosa 2004" TYPE="JOURNAL_ARTICLE">
<AU>Espinosa M, Martín-Malo A, Ojeda R, Santamara R, Soriano S, Aguera M, et al</AU>
<TI>Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>4</NO>
<PG>685-9</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:17:06 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:17:06 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15042545"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fabrizi-2008" MODIFIED="2016-07-04 12:00:43 +1000" MODIFIED_BY="Narelle Willis" NAME="Fabrizi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Fabrizi F, Messa P, Martin P</AU>
<TI>Transmission of hepatitis C virus infection in hemodialysis: current concepts</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>12</NO>
<PG>1004-16</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:14:19 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:14:19 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="19115192"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fabrizi-2012" MODIFIED="2013-04-02 22:21:45 +1100" MODIFIED_BY="[Empty name]" NAME="Fabrizi 2012" TYPE="JOURNAL_ARTICLE">
<AU>Fabrizi F, Dixit V, Messa P</AU>
<TI>Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2012</YR>
<VL>19</VL>
<NO>9</NO>
<PG>601-7</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:21:45 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:21:45 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="22863263"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Finelli-2005" MODIFIED="2016-02-23 13:14:29 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Finelli 2005" TYPE="JOURNAL_ARTICLE">
<AU>Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ</AU>
<TI>National surveillance of dialysis-associated diseases in the United States, 2002</TI>
<SO>Seminars in Dialysis</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>1</NO>
<PG>52-61</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:14:29 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:14:29 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="15663766"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fissell-2004" MODIFIED="2013-04-02 22:22:06 +1100" MODIFIED_BY="[Empty name]" NAME="Fissell 2004" TYPE="JOURNAL_ARTICLE">
<AU>Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al</AU>
<TI>Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>6</NO>
<PG>2335-42</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:21:55 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:21:55 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15149347"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Geddes-2011" MODIFIED="2016-07-04 12:03:18 +1000" MODIFIED_BY="Narelle Willis" NAME="Geddes 2011" TYPE="JOURNAL_ARTICLE">
<AU>Geddes C, Lindley E, Duncan N</AU>
<TI>Renal Association Clinical Practice Guideline on prevention of blood borne virus infection in the renal unit</TI>
<SO>Nephron</SO>
<YR>2011</YR>
<VL>118 Suppl 1</VL>
<PG>c165-88</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:14:36 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:14:36 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="21555895"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Girou-2008" MODIFIED="2013-04-02 22:31:31 +1100" MODIFIED_BY="[Empty name]" NAME="Girou 2008" TYPE="JOURNAL_ARTICLE">
<AU>Girou E, Chevaliez S, Challine D, Thiessart M, Morice Y, Lesprit P, et al</AU>
<TI>Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>5</NO>
<PG>627-33</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:31:31 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:31:31 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18662134"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2013-04-02 22:38:30 +1100" MODIFIED_BY="Jesus Lopez-Alcalde" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JP, Altman DG, Sterne JA</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2013-04-02 22:39:08 +1100" MODIFIED_BY="Jesus Lopez-Alcalde" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JP, Deeks JJ, Altman DG</AU>
<TI>Chapter 16: Special topics in statistics. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hsu-2015" MODIFIED="2016-02-23 13:15:22 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Hsu 2015" TYPE="OTHER">
<AU>Hsu YC, Wu CY, Lin JT</AU>
<TI>Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma</TI>
<SO>Seminars in Oncology</SO>
<YR>2015</YR>
<VL>42</VL>
<NO>2</NO>
<PG>329-38</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:15:22 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:15:22 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="25843737"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jadoul-1998" MODIFIED="2016-07-04 12:05:25 +1000" MODIFIED_BY="Narelle Willis" NAME="Jadoul 1998" TYPE="JOURNAL_ARTICLE">
<AU>Jadoul M, Cornu C, van Ypersele de Strihou C</AU>
<TI>Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group</TI>
<SO>Kidney international</SO>
<YR>1998</YR>
<VL>53</VL>
<NO>4</NO>
<PG>1022-5</PG>
<IDENTIFIERS MODIFIED="2016-07-04 12:05:25 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-07-04 12:05:25 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="9551413"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jadoul-2004" MODIFIED="2013-04-02 22:40:41 +1100" MODIFIED_BY="[Empty name]" NAME="Jadoul 2004" TYPE="JOURNAL_ARTICLE">
<AU>Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, et al</AU>
<TI>The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>4</NO>
<PG>904-9</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:40:41 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:40:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15031348"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jadoul-2012" MODIFIED="2016-02-23 13:15:40 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Jadoul 2012" TYPE="JOURNAL_ARTICLE">
<AU>Jadoul M, Barril G</AU>
<TI>Hepatitis C in hemodialysis: epidemiology and prevention of hepatitis C virus transmission</TI>
<SO>Contributions to Nephrology</SO>
<YR>2012</YR>
<VL>176</VL>
<PG>35-41</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:15:40 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:15:40 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="22310779"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kamili-2007" MODIFIED="2013-04-02 23:06:57 +1100" MODIFIED_BY="[Empty name]" NAME="Kamili 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kamili S, Krawczynski K, McCaustland K, Li X, Alter MJ</AU>
<TI>Infectivity of hepatitis C virus in plasma after drying and storing at room temperature</TI>
<SO>Infection Control &amp; Hospital Epidemiology</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>5</NO>
<PG>519-24</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:40:57 +1100" MODIFIED_BY="Narelle S Willis"><IDENTIFIER MODIFIED="2013-04-02 22:40:57 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17464909"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-KDIGO-2008" MODIFIED="2013-04-02 22:41:36 +1100" MODIFIED_BY="[Empty name]" NAME="KDIGO 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kidney Disease: Improving Global Outcomes (KDIGO)</AU>
<TI>KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease</TI>
<SO>Kidney International - Supplement</SO>
<YR>2008</YR>
<VL>73</VL>
<NO>109</NO>
<PG>S1-99</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:41:35 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:41:35 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18382440"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lee-2014" MODIFIED="2016-07-04 12:08:09 +1000" MODIFIED_BY="Narelle Willis" NAME="Lee 2014" TYPE="JOURNAL_ARTICLE">
<AU>Lee MH, Yang HI, Yuan Y, L'Italien G, Chen CJ</AU>
<TI>Epidemiology and natural history of hepatitis C virus infection</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2014</YR>
<VL>20</VL>
<NO>28</NO>
<PG>9270-80</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:16:19 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:16:19 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="25071320"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mahmoud-2004" MODIFIED="2014-11-11 03:33:25 +1100" MODIFIED_BY="[Empty name]" NAME="Mahmoud 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mahmoud IM, Elhabashi AF, Elsawy E, El-Husseini AA, Sheha GE, Sobh MA</AU>
<TI>The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>1</NO>
<PG>131-9</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="14712436"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marwaha-2014" MODIFIED="2016-07-04 12:09:35 +1000" MODIFIED_BY="Narelle Willis" NAME="Marwaha 2014" TYPE="JOURNAL_ARTICLE">
<AU>Marwaha N, Sachdev S</AU>
<TI>Current testing strategies for hepatitis C virus infection in blood donors and the way forward</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2014</YR>
<VL>20</VL>
<NO>11</NO>
<PG>2948-54</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:16:38 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:16:38 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="24659885"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mbaeyi-2013" MODIFIED="2016-02-23 13:16:49 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Mbaeyi 2013" TYPE="JOURNAL_ARTICLE">
<AU>Mbaeyi C, Thompson ND</AU>
<TI>Hepatitis C virus screening and management of seroconversions in hemodialysis facilities</TI>
<SO>Seminars in Dialysis</SO>
<YR>2013</YR>
<VL>26</VL>
<NO>4</NO>
<PG>439-46</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:16:49 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:16:49 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="23859188"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morales-2012" MODIFIED="2016-02-23 13:16:58 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Morales 2012" TYPE="JOURNAL_ARTICLE">
<AU>Morales JM, Kamar N, Rostaing L</AU>
<TI>Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy</TI>
<SO>Contributions to Nephrology</SO>
<YR>2012</YR>
<VL>176</VL>
<PG>10-23</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:16:58 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:16:58 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="22310777"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Natov-2005" MODIFIED="2016-07-04 12:11:07 +1000" MODIFIED_BY="Narelle Willis" NAME="Natov 2005" TYPE="JOURNAL_ARTICLE">
<AU>Natov SN, Pereira BJ</AU>
<TI>Hepatitis C virus in chronic dialysis patients</TI>
<SO>Minerva Urologica e Nefrologica</SO>
<YR>2005</YR>
<VL>57</VL>
<NO>3</NO>
<PG>175-97</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:17:30 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:17:30 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="15986016"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ozer-Etik-2015" MODIFIED="2016-07-04 12:11:44 +1000" MODIFIED_BY="Narelle Willis" NAME="Ozer Etik 2015" TYPE="JOURNAL_ARTICLE">
<AU>Ozer Etik D, Ocal S, Boyacioglu AS</AU>
<TI>Hepatitis C infection in hemodialysis patients: a review</TI>
<SO>World Journal of Hepatology</SO>
<YR>2015</YR>
<VL>7</VL>
<NO>6</NO>
<PG>885-95</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:17:47 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:17:47 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="25937865"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Patel-2010" MODIFIED="2013-04-02 22:44:02 +1100" MODIFIED_BY="[Empty name]" NAME="Patel 2010" TYPE="JOURNAL_ARTICLE">
<AU>Patel PR, Thompson ND, Kallen AJ, Arduino MJ</AU>
<TI>Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2010</YR>
<VL>56</VL>
<NO>2</NO>
<PG>371-8</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:44:02 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:44:02 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="20570422"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Samandari-2005" MODIFIED="2013-04-02 22:46:03 +1100" MODIFIED_BY="[Empty name]" NAME="Samandari 2005" TYPE="JOURNAL_ARTICLE">
<AU>Samandari T, Malakmadze N, Balter S, Perz JF, Khristova M, Swetnam L, et al</AU>
<TI>A large outbreak of hepatitis B virus infections associated with frequent injections at a physician's office</TI>
<SO>Infection Control &amp; Hospital Epidemiology</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>9</NO>
<PG>745-50</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:46:01 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:46:01 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16209380"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sartor-2004" MODIFIED="2016-07-04 12:13:33 +1000" MODIFIED_BY="Narelle Willis" NAME="Sartor 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sartor C, Brunet P, Simon S, Tamalet C, Berland Y, Drancourt M</AU>
<TI>Transmission of hepatitis C virus between hemodialysis patients sharing the same machine</TI>
<SO>Infection Control &amp; Hospital Epidemiology</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>7</NO>
<PG>609-11</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:18:09 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:18:09 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="15301036"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saune-2011" MODIFIED="2013-04-02 22:46:29 +1100" MODIFIED_BY="[Empty name]" NAME="Saune 2011" TYPE="JOURNAL_ARTICLE">
<AU>Saune K, Kamar N, Miedouge M, Weclawiak H, Dubois M, Izopet J, et al</AU>
<TI>Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>7</NO>
<PG>2309-16</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:46:29 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:46:29 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="21097646"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schneeberger-2000" MODIFIED="2016-07-04 12:14:52 +1000" MODIFIED_BY="Narelle Willis" NAME="Schneeberger 2000" TYPE="JOURNAL_ARTICLE">
<AU>Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, van Haperen AV, et al</AU>
<TI>The prevalence and incidence of hepatitis C virus infections among dialysis patients in The Netherlands: a nationwide prospective study</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2000</YR>
<VL>182</VL>
<NO>5</NO>
<PG>1291-9</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="11023452"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Selm-2010" MODIFIED="2013-04-02 22:49:15 +1100" MODIFIED_BY="[Empty name]" NAME="Selm 2010" TYPE="JOURNAL_ARTICLE">
<AU>Selm SB</AU>
<TI>Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen</TI>
<SO>Saudi Journal of Kidney Diseases &amp; Transplantation</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>6</NO>
<PG>1165-8</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:49:15 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:49:15 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="21060200"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Selvarajah-2012" MODIFIED="2016-02-23 13:18:29 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Selvarajah 2012" TYPE="JOURNAL_ARTICLE">
<AU>Selvarajah S, Busch MP</AU>
<TI>Transfusion transmission of HCV, a long but successful road map to safety</TI>
<SO>Antiviral Therapy</SO>
<YR>2012</YR>
<VL>17</VL>
<NO>7 Pt B</NO>
<PG>1423-9</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:18:29 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:18:29 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="23322562"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shimokura-2011" MODIFIED="2013-04-02 22:51:33 +1100" MODIFIED_BY="[Empty name]" NAME="Shimokura 2011" TYPE="JOURNAL_ARTICLE">
<AU>Shimokura G, Chai F, Weber DJ, Samsa GP, Xia GL, Nainan OV, et al</AU>
<TI>Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients</TI>
<SO>Infection Control &amp; Hospital Epidemiology</SO>
<YR>2011</YR>
<VL>32</VL>
<NO>5</NO>
<PG>415-24</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:51:33 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:51:33 +1100" MODIFIED_BY="Jesus Lopez-Alcalde" TYPE="MEDLINE" VALUE="21515970"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Su-2013" MODIFIED="2016-02-23 13:18:57 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Su 2013" TYPE="JOURNAL_ARTICLE">
<AU>Su Y, Norris JL, Zang C, Peng Z, Wang N</AU>
<TI>Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis</TI>
<SO>Hemodialysis International</SO>
<YR>2013</YR>
<VL>17</VL>
<NO>4</NO>
<PG>532-41</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:18:46 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:18:46 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="23072424"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sun-2009" MODIFIED="2016-07-04 12:17:30 +1000" MODIFIED_BY="Narelle Willis" NAME="Sun 2009" TYPE="JOURNAL_ARTICLE">
<AU>Sun J, Yu R, Zhu B, Wu J, Larsen S, Zhao W</AU>
<TI>Hepatitis C infection and related factors in hemodialysis patients in China: systematic review and meta-analysis</TI>
<SO>Renal Failure</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>7</NO>
<PG>610-20</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:52:57 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:52:57 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19839861"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thompson-2009" MODIFIED="2013-04-02 22:53:20 +1100" MODIFIED_BY="[Empty name]" NAME="Thompson 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thompson ND, Novak RT, Datta D, Cotter S, Arduino MJ, Patel PR, et al</AU>
<TI>Hepatitis C virus transmission in hemodialysis units: importance of infection control practices and aseptic technique</TI>
<SO>Infection Control &amp; Hospital Epidemiology</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>9</NO>
<PG>900-3</PG>
<IDENTIFIERS MODIFIED="2013-04-02 22:53:20 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 22:53:20 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19642900"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2016-07-04 12:18:57 +1000" MODIFIED_BY="Narelle Willis" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment (Winchester, England)</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS MODIFIED="2013-04-02 23:01:47 +1100" MODIFIED_BY="Narelle S Willis"><IDENTIFIER MODIFIED="2013-04-02 23:01:47 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10982317"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Valtuille-2002" MODIFIED="2008-10-09 10:03:49 +1100" MODIFIED_BY="Leslee Edwards" NAME="Valtuille 2002" TYPE="JOURNAL_ARTICLE">
<AU>Valtuille R, Moretto H, Lef L, Rendo P, Fernandez JL</AU>
<TI>Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up</TI>
<SO>Clinical Nephrology</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>5</NO>
<PG>371-5</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="12036197"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vladutiu-2000" MODIFIED="2013-04-02 23:03:06 +1100" MODIFIED_BY="Leslee Edwards" NAME="Vladutiu 2000" TYPE="JOURNAL_ARTICLE">
<AU>Vladutiu DS, Cosa A, Neamtu A, State D, Braila M, Gherman M, et al</AU>
<TI>Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map?</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>4</NO>
<PG>313-9</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="10886543"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Voiculescu-2010" MODIFIED="2013-04-02 23:04:39 +1100" MODIFIED_BY="[Empty name]" NAME="Voiculescu 2010" TYPE="JOURNAL_ARTICLE">
<AU>Voiculescu M, Iliescu L, Ionescu C, Micu L, Ismail G, Zilisteanu D, et al</AU>
<TI>A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania</TI>
<SO>Journal of Gastrointestinal &amp; Liver Diseases</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>1</NO>
<PG>43-8</PG>
<IDENTIFIERS MODIFIED="2013-04-02 23:04:39 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 23:04:39 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="20361074"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Webster-2015" MODIFIED="2016-02-23 13:19:32 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Webster 2015" TYPE="JOURNAL_ARTICLE">
<AU>Webster DP, Klenerman P, Dusheiko GM</AU>
<TI>Hepatitis C</TI>
<SO>Lancet</SO>
<YR>2015</YR>
<VL>385</VL>
<NO>9973</NO>
<PG>1124-35</PG>
<IDENTIFIERS MODIFIED="2016-02-23 13:19:32 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-02-23 13:19:32 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="25687730"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Williams-2004" MODIFIED="2013-04-02 23:05:02 +1100" MODIFIED_BY="[Empty name]" NAME="Williams 2004" TYPE="JOURNAL_ARTICLE">
<AU>Williams J</AU>
<TI>Guidelines to determine who should be tested for hepatitis C</TI>
<SO>Nursing Times</SO>
<YR>2004</YR>
<VL>100</VL>
<NO>28</NO>
<PG>28-9</PG>
<IDENTIFIERS MODIFIED="2013-04-02 23:05:02 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-02 23:05:02 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15311533"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-07-04 12:24:59 +1000" MODIFIED_BY="Narelle Willis">
<REFERENCE ID="REF-Bravo-Zuniga-2007" MODIFIED="2016-07-04 12:24:59 +1000" MODIFIED_BY="Narelle Willis" NAME="Bravo Zuniga 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Bravo Zuñiga JI, Loza Munarriz C, López-Alcalde J</AU>
<TI>Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-07-04 12:24:56 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-07-04 12:24:56 +1000" MODIFIED_BY="Narelle Willis" TYPE="DOI" VALUE="10.1002/14651858.CD006420"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-05-16 13:52:52 +1000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-08-04 13:40:49 +1000" MODIFIED_BY="Narelle S Willis">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-08-04 13:40:49 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-08-04 13:40:49 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Shamshirsaz-2004">
<CHAR_METHODS MODIFIED="2016-08-04 13:40:49 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: cluster RCT; they randomly selected centres one by one to reach a total number of 593 patients (12 centres)</LI>
<LI>Study duration: 2 years</LI>
<LI>Duration of follow-up: 442 patients (254 cases in the treatment group and 192 in the control group) were followed for 9 months. 281 patients (160 in the treatment group and 121 in the control group) were followed for an additional 9 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-06 16:08:10 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Setting: multi-centre</LI>
<LI>Country: Iran</LI>
<LI>ELISA III checked all patients for HCV antibody detection before enrolling in the study, positive cases were confirmed by RT-PCR</LI>
<LI>Number: 593 enrolled</LI>
<UL>
<LI>&#9702; Treatment group: 297; 267 negatives and 30 positives by HCV</LI>
<LI>&#9702; Control group: 296; 275 negatives and 21 positives by HCV</LI>
</UL>
<LI>Mean age ± SE (years): treatment group (48.1 ± 0.9); control group (50.6 ± 1.0)</LI>
<LI>Sex (% male): treatment group (59.9); control group (54.2)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-06 16:38:34 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Centres with dedicated HD machines</LI>
<LI>Dialysis membranes were low pressure and used only once and HD machines were bleached and rinsed between dialysis sessions according to the manufacturers' instruction. All machines were located in dialysis wards and not in separate rooms in both groups.</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Centres with no dedicated HD machines</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-06 15:59:32 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Incidence of HCV infection in both groups, to evaluate the effect of dialysis machine separation on the spread of HCV infection</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-06 16:23:12 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>To prevent HCV transmission, educational courses were held for the staff to re-emphasize the CDC hygienic guidelines</LI>
<LI>Patients were dialyzed for 4 or 4.5 hours, 2 or 3 times/week, using standard HD techniques, patient to staff ratio in the groups wasn't statistically different (3.1 and 3.4 respectively) and all staff members were negative for anti-HCV</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CDC - Centers for Disease Control and Prevention; HCV - hepatitis C virus; HD - haemodialysis; SE - standard error</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-07-06 17:32:11 +1000" MODIFIED_BY="Narelle Willis" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-07-06 16:45:38 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Agarwal-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-06 16:45:38 +1000" MODIFIED_BY="Narelle Willis">
<P>Cohort study 2003 to 2006, room isolation, HCV seroconversion from 42% in 1995 to 1998 (without isolation) to 4% in 2003 to 2006 (with isolation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-10 15:15:28 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Barril-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-10 15:15:28 +1000" MODIFIED_BY="Narelle Willis">
<P>Cohort, multicentre study: 44 centres, room isolation, evaluate prevalence of hepatitis C and time, it divide its population in 4 quartiles according prevalence of hepatitis C, after isolation they observe decrease of seroconversion in all quartiles</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-06 16:46:01 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Gallego-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-06 16:46:01 +1000" MODIFIED_BY="Narelle Willis">
<P>Analytic study, comparing two periods of 1993 to 1995 in which isolation of machines for patients with hepatitis C is applied, and where are 2 seroconversions and second period 1996 to 2003 applied isolation room and staff, which do not show any seroconversion. Progressive decline observed prevalence of hepatitis C in its population 30.5% vs 6.8%</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-06 16:46:18 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Garcia_x002d_Valdecasas-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-06 16:46:18 +1000" MODIFIED_BY="Narelle Willis">
<P>Analytic study, three rooms of dialysis: Room A: 27 patients and 6 HCV (+), Room B: 28 patients; 7 HCV (+), Room C: 25 patients, 14 with HCV (+); No isolation: 1990, 1991 to 1992 isolation of machine only in rooms A and B, isolation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-10 15:33:16 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Huang-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-10 15:33:16 +1000" MODIFIED_BY="Narelle Willis">
<P>Prospective study, from April 1992, 32 patients negative for HCV, isolated machine and room, after 14.2 + 3 months, a patient seroconverted, apparently associated with blood transfusion, seroconversion rate 14.6% versus 3.1% prior to isolation (historical data)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-06 16:26:42 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Mohamed-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-06 16:26:42 +1000" MODIFIED_BY="Narelle Willis">
<P>Prospective study was conducted on 36 seronegative HD patients. All patients were managed with strict application of infection control guidelines as well as isolation of HCV-positive patients. After five years of follow-up, They found that the incidence of HCV seroconversion was zero.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-06 16:52:05 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Ross-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-06 16:52:05 +1000" MODIFIED_BY="Narelle Willis">
<P>Large prospective multicentre study was conducted. In the first and second rounds, 150 (5.2%) of 2909 and 114 (5.4%) of 2100 patients were anti-HCV positive, respectively, and 4% of individuals were viraemic.</P>
<P>20% of these patients no nosocomial Hepatitis C transmission occurred during the observational period suggests that the lack of HCV seroconversions was not only attributable to the isolation of HCV-infected patients but also to the strict adherence universal hygienic precautions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-06 16:48:43 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Saxena-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-06 16:48:43 +1000" MODIFIED_BY="Narelle Willis">
<P>Retrospective study, In the first phase, 189 patients who were receiving maintenance HD from 1995 to 2000 were studied about prevalence of HCV. Phase II involved stringent isolation of anti-HCV positive patients detected during phase, with dedicated space, dialysis equipment, and nursing staff from December 2000 to December 2001. Prevalence rate of 43.9% (83/189) and an annual HCV seroconversion rate of 6.8% were identified in this cohort. Only 2 new HCV seroconversions (1.01% (2/198)) were identified after isolation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-06 16:39:11 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Shebeb-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-06 16:39:11 +1000" MODIFIED_BY="Narelle Willis">
<P>This study compared strict adherence to the universal precautions and anti HCV seropositive patient isolation. Three units: A: education intervention program, 30 patients and 12 staff personal, B: none of the preventive measures were applied, 66 patients nursed by 16 staff C: had 67 patients nursed by 27 staff. The incidence rate of anti HCV seroconversion decreased in unit A from (10% to 0%), and in unit C from (24.4% to 10%), 6 months of the follow. It increased in unit B, where no measure was taken, from 10.5% to 16.7%.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-10 15:01:55 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Valtuille-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-10 15:01:55 +1000" MODIFIED_BY="Narelle Willis">
<P>Study applying extreme conditions of permeability to the dialysis membrane and avoiding the use of heparin and dialysis bath. They obtained samples from the ultrafiltrate at the beginning of 18 HD sessions carried out in 6 HCV RNA-positive patients. HCV RNA was detected by PCR in 3 (16.7%) ultrafiltrate samples belonging to 1 of the patients. HCV genotype was the same as that found in positive ultrafiltrate samples and in the serum corresponding to this patient.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-06 17:32:07 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Yang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-06 17:32:07 +1000" MODIFIED_BY="Narelle Willis">
<P>Retrospective study, 325 HD patients from1993 to 2000 were included, isolation started after 1997. Patients positive for either hepatitis B or C were clustered in 1 area. Anti-HCV-negative and HBsAg - negative patients were assigned either to a segregated zone (Area 2) in the same room or to a separate independent room (Area 3). Forty months after the implementation of the isolation policy, there was significant reduction in the total prevalence (49.7 vs 31.7%) and incidence (9.1 vs 2.9 % patient-years) of HCV infection.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>HBsAg - hepatitis B surface antigen; HCV - hepatitis C virus; HD - haemodialysis</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-05-24 08:58:43 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-11-11 03:45:45 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-08-04 11:35:04 +1000" MODIFIED_BY="Narelle S Willis">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-07-06 16:13:37 +1000" MODIFIED_BY="Narelle Willis" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-06 16:13:37 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shamshirsaz-2004">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
<P>Randomisation was performed by dialysis centre, it was a cluster randomised trial which included four centres (intervention) compared with eight centres (control)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-07-06 16:09:38 +1000" MODIFIED_BY="Narelle Willis" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-06 16:09:38 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Shamshirsaz-2004">
<DESCRIPTION>
<P>Allocation concealment was not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-08-04 10:53:11 +1000" MODIFIED_BY="Narelle S Willis" NO="9">
<NAME>Was recruitment bias adequately prevented?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-04 10:52:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shamshirsaz-2004">
<DESCRIPTION>
<P>Individuals were recruited to the trial after the clusters had been randomised (the knowledge of whether each cluster is an &#8216;intervention&#8217; or &#8216;control&#8217; cluster could affect the types of participants recruited).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2016-08-04 11:35:04 +1000" MODIFIED_BY="Narelle S Willis" NO="10">
<NAME>Were baseline imbalances (in terms of either the clusters or the individuals) adequately addressed?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-04 10:52:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shamshirsaz-2004">
<DESCRIPTION>
<P>There were baseline imbalances between the randomised groups, but finally they were not controlled for at the design or analysis stage of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-07-29 06:44:43 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-07-29 06:44:43 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-06 16:10:13 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Shamshirsaz-2004">
<DESCRIPTION>
<P>There was no blinding of participants or personnel<BR/>
<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-07-29 06:44:43 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-06 16:12:13 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shamshirsaz-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgement<BR/>
</P>
<P>
<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-08-04 10:53:43 +1000" MODIFIED_BY="Narelle S Willis" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-08-04 10:53:43 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shamshirsaz-2004">
<DESCRIPTION>
<P>Intention-to-treat analysis was not performed. There was an "available case analysis" done with substantial departure of the intervention received from that assigned at randomisation.<BR/>
</P>
<P>Only 74.5% of the patients were followed for 9 months and 47.3% were followed for an additional 9 months</P>
<P>They lost &gt; 10% of their population</P>
<P>One centre was excluded after randomisation, causing a deviation from protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-07-29 06:44:43 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-06 16:26:37 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Shamshirsaz-2004">
<DESCRIPTION>
<P>The authors only reported one result, measuring the difference in the incidence of HCV in both groups, based on that issued its findings, did not have secondary outcomes.</P>
<P>The authors did not consider the exposure time (i.e. years patients at risk) in determining the rate of seroconversion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-07-29 06:47:56 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2016-08-04 10:53:33 +1000" MODIFIED_BY="Narelle S Willis" NO="11">
<NAME>Was the study analysed by correct statistical methods (i.e. taking the clustering into account)?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-04 10:53:33 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shamshirsaz-2004">
<DESCRIPTION>
<P>"Comparisons between groups were made by the chi square test method for categorical variables and by the t test for quantitative variables."</P>
<P>The cluster-randomised trial was analysed by incorrect statistical methods, not taking the clustering into account</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-08-04 10:55:02 +1000" MODIFIED_BY="Narelle S Willis">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-08-04 10:55:02 +1000" MODIFIED_BY="Narelle S Willis" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-08-04 10:54:22 +1000" MODIFIED_BY="Narelle S Willis">Dialysis machine separation versus usual care</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>Should patients with HCV be isolated in haemodialysis units for controlling the transmission of HCV?</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>patients in haemodialysis<BR/>
<B>Setting: </B>ambulatory</P>
<P>
<B>Intervention: </B>isolation<BR/>
<B>Comparison: </B>usual care</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with usual care</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with isolation</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Incidence of HCV infection (9 months)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.34<BR/>(0.11 to 1.07)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>446 (1)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>VERY LOW</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Very low quality of evidence due to high risk of bias and imprecision</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>47 per 1.000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>16 per 1.000<BR/>(5 to 50)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Incidence of HCV infection (18 months)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.22<BR/>(0.05 to 1.02)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>281 (1)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>VERY LOW</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Very low quality of evidence due to high risk of bias and imprecision</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>58 per 1.000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>13 per 1.000<BR/>(3 to 59)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-08-05 01:10:08 +1000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-08-04 10:52:03 +1000" MODIFIED_BY="Narelle S Willis">
<COMPARISON ID="CMP-001" MODIFIED="2016-08-04 10:52:03 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Dialysis machine separation vs Usual care</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-08-04 10:51:53 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="254" TOTAL_2="192" WEIGHT="0.0" Z="0.0">
<NAME>Incidence of HCV infection: 9 months</NAME>
<GROUP_LABEL_1>Isolation</GROUP_LABEL_1>
<GROUP_LABEL_2>Usual care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours isolation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours usual care</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.074669209883909" CI_START="0.10502560253243942" EFFECT_SIZE="0.3359580052493438" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.031274806177572716" LOG_CI_START="-0.9787048182330745" LOG_EFFECT_SIZE="-0.47371500602775096" MODIFIED="2016-08-03 06:19:41 +1000" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.5932670308585857" STUDY_ID="STD-Shamshirsaz-2004" TOTAL_1="254" TOTAL_2="192" VAR="0.35196576990376205" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-08-04 10:52:03 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="160" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>Incidence of HCV infection: 18 months</NAME>
<GROUP_LABEL_1>Isolation</GROUP_LABEL_1>
<GROUP_LABEL_2>Usual care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours isolation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours usual care</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0217117123523678" CI_START="0.04569475095612549" EFFECT_SIZE="0.21607142857142858" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.009328371927405004" LOG_CI_START="-1.3401336853069055" LOG_EFFECT_SIZE="-0.6654026566897503" MODIFIED="2016-08-03 06:22:16 +1000" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.7926806923643501" STUDY_ID="STD-Shamshirsaz-2004" TOTAL_1="160" TOTAL_2="121" VAR="0.6283426800472255" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-08-04 11:35:05 +1000" MODIFIED_BY="Narelle S Willis">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-08-04 11:00:51 +1000" MODIFIED_BY="Narelle S Willis" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA1UAAAGJCAYAAABinBm7AAA7NElEQVR42u3df8RW9+M/8JGZZDKS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-08-04 11:35:05 +1000" MODIFIED_BY="Narelle S Willis" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across one included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0UAAAEyCAMAAAAC4YvXAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-08-04 11:35:05 +1000" MODIFIED_BY="Narelle S Willis" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for one included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAY8AAAJaCAIAAABY41yxAAAboUlEQVR42u3dsY5kSZWH8ZaQEMYY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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-07-06 16:44:57 +1000" MODIFIED_BY="Narelle Willis">
<APPENDIX ID="APP-01" MODIFIED="2015-07-06 15:20:59 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-05-17 10:59:44 +1000" MODIFIED_BY="Narelle S Willis">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-07-06 15:20:59 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>CENTRAL</P>
</TD>
<TD>
<OL>
<LI>MeSH descriptor: [Renal Dialysis] this term only</LI>
<LI>MeSH descriptor: [Hemofiltration] explode all trees</LI>
<LI>dialysis or hemodialysis or haemodialysis in Trials</LI>
<LI>hemofiltration or haemofiltration in Trials</LI>
<LI>hemodiafiltration or haemodiafiltration in Trials</LI>
<LI>#1 or #2 or #3 or #4 or #5</LI>
<LI>MeSH descriptor: [Hemodialysis Units, Hospital] this term only</LI>
<LI>((hemodialysis or haemodialysis or dialysis) and (centre* or centre* or unit* or department* or hospital* or facilit* or clinic*)) in Trials</LI>
<LI>MeSH descriptor: [Outpatient Clinics, Hospital] explode all trees</LI>
<LI>MeSH descriptor: [Ambulatory Care Facilities] explode all trees</LI>
<LI>#7 or #8 or #9 or #10</LI>
<LI>MeSH descriptor: [Hepatitis C] explode all trees</LI>
<LI>MeSH descriptor: [Hepacivirus] this term only</LI>
<LI>"hepatitis c" in Trials</LI>
<LI>hcv in Trials</LI>
<LI>#12 or #13 or #14 or #15</LI>
<LI>MeSH descriptor: [Cross Infection] explode all trees</LI>
<LI>MeSH descriptor: [Infection Control] explode all trees</LI>
<LI>MeSH descriptor: [Universal Precautions] explode all trees</LI>
<LI>infection control* in Trials</LI>
<LI>isolat* in Trials</LI>
<LI>#17 or #18 or #19 or #20 or #21</LI>
<LI>#6 and #11 and #16 and #22</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<OL>
<LI>Renal Dialysis/</LI>
<LI>exp Hemofiltration/</LI>
<LI>dialysis.tw.</LI>
<LI>(hemodialysis or haemodialysis).tw.</LI>
<LI>(hemofiltration or haemofiltration).tw.</LI>
<LI>(hemodiafiltration or haemodiafiltration).tw.</LI>
<LI>or/1-6</LI>
<LI>Hemodialysis Units, Hospital/</LI>
<LI>((hemodialysis$ or haemodialysis$ or dialysis$) and (centre$ or centre$ or unit$ or department$ or hospital$ or facilit$ or clinic$)).tw.</LI>
<LI>ambulatory care facilities/ or outpatient clinics, hospital/</LI>
<LI>or/8-10</LI>
<LI>exp Hepatitis C/</LI>
<LI>"hepatitis c".tw.</LI>
<LI>HCV.tw.</LI>
<LI>Hepacivirus/</LI>
<LI>or/12-15</LI>
<LI>Cross Infection/</LI>
<LI>exp Infection Control/</LI>
<LI>infection control$.tw.</LI>
<LI>isolat$.tw.</LI>
<LI>Universal Precautions/</LI>
<LI>or/17-21</LI>
<LI>7 and 11 and 16 and 22</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE</P>
</TD>
<TD>
<OL>
<LI>hemodialysis/</LI>
<LI>((hemodialysis$ or haemodialysis$ or dialysis$) and (centre$ or centre$ or unit$ or department$ or hospital$ or facilit$ or clinic$)).tw.</LI>
<LI>outpatient department/</LI>
<LI>or/1-3</LI>
<LI>hepatitis C/</LI>
<LI>Hepatitis C virus/</LI>
<LI>"hepatitis c".tw.</LI>
<LI>HCV.tw.</LI>
<LI>or/5-8</LI>
<LI>infection control/</LI>
<LI>infection control$.tw.</LI>
<LI>patient care/</LI>
<LI>isolat$.tw.</LI>
<LI>or/10-13</LI>
<LI>4 and 9 and 14</LI>
</OL>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-05-01 17:13:31 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<TITLE MODIFIED="2012-05-17 11:00:21 +1000" MODIFIED_BY="Narelle S Willis">Risk of bias assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-01 17:13:31 +1000" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="19">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</TD>
<TD>
<P>
<I>Low risk of bias</I>: No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias</I>: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
<P>Reporting bias due to selective outcome reporting</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-07-06 16:44:57 +1000" MODIFIED_BY="Narelle Willis" NO="3">
<TITLE MODIFIED="2015-07-06 15:21:47 +1000" MODIFIED_BY="[Empty name]">Risk of bias assessment tool for cluster randomised studies</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-06 16:44:57 +1000" MODIFIED_BY="Narelle Willis">
<TABLE COLS="2" ROWS="11">
<TR>
<TH>
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH>
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Was recruitment bias adequately prevented?</B>
</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Individuals were not recruited to the trial after the clusters had been randomised.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> Individuals were recruited to the trial after the clusters had been randomised (the knowledge of whether each cluster is an &#8216;intervention&#8217; or &#8216;control&#8217; cluster could affect the types of participants recruited).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear risk of bias:</I> Insufficient information to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Were baseline imbalances (in terms of either the clusters or the individuals) adequately addressed?</B>
</P>
</TD>
<TD>
<P>
<I>Low risk of bias:</I> The randomised groups were similar at baseline; or the randomised groups were imbalanced at baseline but finally controlled for at the design (such as using stratified or pair matched randomisation of clusters) or analysis stage of the study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> There were baseline imbalances between the randomised groups, but finally they were not controlled for at the design or analysis stage of the study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear risk of bias:</I> Insufficient information to permit judgement.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Were loss of clusters and participants adequately addressed?</B>
</P>
</TD>
<TD>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>: "Incomplete outcome data" for criteria of how we will assess this domain.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Was the study analysed by correct statistical methods (i.e. taking the clustering into account)?</B>
</P>
</TD>
<TD>
<P>
<I>Low risk of bias:</I> The cluster-randomised trial was analysed by correct statistical methods, taking the clustering into account. Ways to avoid unit-of-analysis errors in cluster-randomised trials are (see Cochrane Handbook 16.3.3, <LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>): to conduct the analysis at the same level as the allocation; to conduct the analysis at the level of the individual while accounting for the clustering in the data. Such an analysis might be based on a &#8216;multilevel model&#8217;, a &#8216;variance components analysis&#8217; or a &#8216;generalized estimating equations (GEEs)&#8217;, among other techniques.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> The cluster-randomised trial was analysed by incorrect statistical methods, not taking the clustering into account. Such analyses tend to create a &#8216;unit of analysis error&#8217; and produce over-precise results (the standard error of the estimated intervention effect is too small) and P values that are too small. Although they do not lead to biased estimates of effect, if they remain uncorrected, they will receive too much weight in a meta-analysis.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear risk of bias: </I>insufficient information to permit judgement.</P>
</TD>
</TR>
</TABLE>
<P>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_C106432182E26AA2007834EBF3D23A1A_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="C106432182E26AA2007834EBF3D23A1A">
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Hospital Edgardo Rebagliati</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Lima</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="PE">Peru</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_EF8630AA82E26AA201B664BB681855E6_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="EF8630AA82E26AA201B664BB681855E6">
<ADDRESS>
<DEPARTMENT>Faculty of Medicine</DEPARTMENT>
<ORGANISATION>Universidad Francisco de Vitoria (UFV) Madrid</ORGANISATION>
<ADDRESS_1>ctra. Pozuelo-Majadahonda km. 1,800</ADDRESS_1>
<ADDRESS_2/>
<CITY>Madrid</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>(+34) 91 3368103</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included studies: 1 (593 participants)&lt;/p&gt;" WIDTH="250">
<FLOWCHARTBOX TEXT="&lt;p&gt;Full-text articles assessed: 12&lt;/p&gt;" WIDTH="250">
<FLOWCHARTBOX TEXT="&lt;p&gt;Titles and abstracts screened: 105&lt;/p&gt;" WIDTH="250">
<FLOWCHARTBOX TEXT="&lt;p&gt;Total number of records: 126&lt;/p&gt;" WIDTH="250">
<FLOWCHARTBOX TEXT="&lt;p&gt;Electronic databases: 126 records&lt;br&gt;(Specialised Register, CENTRAL, MEDLINE, EMBASE)&lt;/p&gt;" WIDTH="400"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Other resources: 0&lt;/p&gt;" WIDTH="400"/>
<OUT TEXT="&lt;p&gt;Duplicate records: 21&lt;/p&gt;" WIDTH="220"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Records excluded: 93 (&lt;span&gt;not RCT)&lt;/span&gt;&lt;/p&gt;" WIDTH="220"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Excluded studies: 11&lt;br&gt;(Not RCT)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="220"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>